# Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

> **NCT07172958** · PHASE1 · RECRUITING · sponsor: **Children's National Research Institute** · enrollment: 18 (estimated)

## Conditions studied

- Rhabdomyosarcoma
- Ewing Sarcoma
- Neuroblastoma
- Wilms Tumor

## Interventions

- **BIOLOGICAL:** Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells

## Key facts

- **NCT ID:** NCT07172958
- **Lead sponsor:** Children's National Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-27
- **Primary completion:** 2035-12
- **Final completion:** 2038-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-01-27

## Collaborators

- National Cancer Institute (NCI)
- Cancer Research UK
- The Mark Foundation for Cancer Research

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07172958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07172958, "Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07172958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*